Coati-X EU Project Unveils Innovative Technology to Revolutionize Medical Device Safety

Liège, Belgium – April 1, 2024 – CMD-COAT, a leading research and development company, and FRESCI, experts in health innovation, are proud to announce the launch of Coati-X, a groundbreaking project funded by the European Innovation Council to deliver a proprietary bioactive coating technology designed to enhance the safety and effectiveness of intravenous catheters and implantable medical devices. This new generation of coatings aims to prevent two major complications: infections and thrombosis.

Innovative Technology to Address Critical Medical Needs

Intravenous catheters and implantable medical devices are essential tools in modern healthcare, but they come with significant risks. Catheter-related bloodstream infections and thrombosis are major causes of patient morbidity and mortality, leading to prolonged hospital stays and increased healthcare costs. CMD-COAT addresses these challenges by offering a coating that combines anti-thrombotic, anti-microbial, hydrosoluble, and biocompatible properties.

Four Key Technical Features of CMD-COAT Solution:

1. Anti-Thrombotic: Prevents blood clots from forming on the device surface, reducing the risk of thrombosis.
2. Anti-Microbial: Provides effective protection against a wide range of harmful microorganisms, preventing infections.
3. Hydrosoluble: Utilizes a water-based, non-toxic formulation that does not degrade the medical device material.
4. Biocompatibility: Ensures compatibility with human tissues, minimizing adverse reactions and ensuring safe integration with the body.

Innovative Cross-Linked Nanogels

CMD-COAT employs a unique layer-by-layer assembly of cross-linked nanogels that can be loaded with anti-thrombotic and antibiotic drugs. This innovative design allows for controlled, localized release of bioactive agents, significantly enhancing the coating’s duration of effectiveness. The nanoreservoirs created by these nanogels can entrap multiple bioactive molecules, combining several biological activities in a single coating. This technology is adaptable to various biomaterials, including metallic, biological, and polymeric surfaces.

Project Consortium and Market Strategy

CMD-COAT leads a consortium that brings together top researchers, cardiovascular specialists, biologists, chemists, and FRESCI business strategists. Together, they aim to accelerate the development and validation of this coating technology, bringing this innovative solution to market readiness.

Market Potential and Strategic Partnerships

The first applications of Coati-X will focus on central venous catheters (CVCs) and peripherally inserted central catheters, which are commonly used in medical practice and associated with high risks of infection and thrombosis. CMD-COAT is going to partner with major medical device manufacturers to leverage their production capabilities, regulatory experience, and distribution networks.

Intellectual Property and Future Developments

CMD-COAT holds several patents for the Coati-X technology and its applications. The company plans to file additional patents and trademarks to expand its intellectual property portfolio. Future developments during the Coati-X project include adapting the technology for other cardiovascular devices such as stents, heart valves and pacemakers.

CMD-COAT’s Commitment to Innovation

«Our mission at CMD-COAT is to revolutionize the safety and effectiveness of medical devices through innovative coating technologies,» said Professor Patrizio Lancellotti, Head of the Cardiology Department at Liège University Hospital and co-founder of CMD-COAT. «Coati-X represents a significant advancement in preventing the two most frequent and severe complications associated with medical devices.»

About FRESCI

FRESCI by SCIENCE&STRATEGY SL is dedicated to enhancing the impact of research in human health through strategic consultancy and evidence-based solutions. Specializing in strategic and organizational development, research and analysis, funding and financial planning, and stakeholder engagement, FRESCI supports organizations across public, private, and philanthropic sectors. By amplifying the value of research results, FRESCI aims to foster reproducibility, sustainability, and innovation in science, business, and regulation.

For more information, visit FRESCI.

About CMD-COAT

CMD-COAT is a spin-off company of Liège University, dedicated to developing bioactive coatings for medical devices. Founded in 2021, CMD-COAT leverages cutting-edge research and collaboration with leading medical and scientific institutions to bring innovative solutions to market. The company’s flagship product, Coati-X, is set to transform the landscape of medical device safety and efficacy.

For more information, visit CMD-COAT’s website or contact:

Media Contact:

Sébastien Cajot, PhD
COO, CMD-COAT
Email: sebastien.cajot@cmd-coat.com
Phone: +32 4 366 93 00

CMD-COAT: Innovating for Safer Healthcare